

National Radiology Data Registry

Facility Report, Dec 2022

Public Facility
(Facility ID: 100853)



nrdr.acr.org



This page is intentionally blank.

Lung Cancer Screening Registry Report from the American College of Radiology

We are pleased to release the Jan-Dec 2023 quarterly Lung Cancer Screening Registry reports. The PDF report contains the following:

Section 1: Facility level data, 2023

This section provides a list of LCSR measures calculated from data submitted during Jan-Dec 2023. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 1 is provided only for those facilities that have submitted data during 2023.

Section 2: Facility level data, 2022

This section provides a list of LCSR measures calculated from data submitted during Jan-Dec 2022. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 2 is provided only for those facilities that submitted data during 2022.

Demographic Data


The bar charts describe demographic data of all the facilities that contributed data during 2022 and 2023.

Maintenance of Certification (MOC):Practice Quality Improvement (PQI).

We have listed the physicians participating in LCSR at your facility and their NPI's.

We exclude exams without NPI information for the interpreting radiologist as it is a required field for CMS submission, in our role as a CMS approved registry.

LCSR Facilities



Black dots indicate LCSR facilities that contributed data for this report

Facility ID=100853

Page 4

31Dec2022

LCSR Measure Definitions

Measure	Description
First-time screening	Percent of screenings for first-time patients out of all screenings
Appropriateness of screening by 2013 USPSTF criteria	Percent of screening population who are adults aged 55 to 80 years, have a 30 pack-year smoking history, and currently smoke or have quit within the past 15 years.
Appropriateness of screening by 2021 USPSTF criteria	Percent of screening population who are adults aged 50 to 80 years, have a 20 pack-year smoking history, and currently smoke or have quit within the past 15 years.
Smoking cessation offered	Percent of patients who are offered smoking cessation guidance.
Smoking cessation offered among current smokers	Percent of current smokers who are offered smoking cessation guidance.
Non-smoking rate	Percent of patients reporting as Former Smoker out of all patients reporting as Current Smoker, Former Smoker, or Smoker, Current Status Unknown
Adherence to annual screening	Percent of patients with follow-up exam 11-15 months after previous screening (where previous screening met appropriateness criteria and had Lung RADS 1 or 2)
Adherence to 6-months interim assessment	Number and percent of patients meeting the 6-months follow-up timeline after receiving a Lung RADS 3 on a screening exam.
Adherence to 3-months interim assessment	Number and percent of patients meeting the 3-months follow-up timeline after receiving a Lung RADS 4A on a screening exam.
Radiation exposure 1 Mean CT DIvol - overall	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed.
Radiation exposure 1 Mean CT DIvol underweight (BMI <18.5)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on underweight patients (BMI<18.5).
Radiation exposure 1 Mean CT DIvol healthy weight (BMI of 18.5–24.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on healthy weight patients (BMI of 18.5-24.9).
Radiation exposure 1 Mean CT DIvol overweight (BMI of 25–29.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on overweight patients (BMI of 25-29.9).
Radiation exposure 1 Mean CT DIvol obese (BMI of 30 or more)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on obese patients (BMI of 30 or more).
Radiation exposure 1 Mean CT DIvol obese class I (BMI of 30-34.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class I obese patients (BMI of 30-34.9).

LCSR Measure Definitions

Measure	Description
Radiation exposure 1 Mean CTDIvol obese class II (BMI of 35-39.9)	Mean Volumetrics CT Dose Index (CTDIvol) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 1 Mean CTDIvol obese class III (BMI of 40 or greater)	Mean Volumetrics CT Dose Index (CTDIvol) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 1 Mean CTDIvol - low dose chest exams	Mean Volumetrics CT Dose Index (CTDIvol) across other than routine (low dose) chest exams performed.
Radiation exposure 1 Mean CTDIvol - routine chest exams	Mean Volumetrics CT Dose Index (CTDIvol) across routine chest exams performed.
Radiation exposure (DLP)	Mean Dose Length Product (DLP) across all screening exams performed.
Radiation exposure 2 Mean DLP underweight (BMI <18.5)	Mean Dose Length Product (DLP) across all screening exams performed on underweight patients (BMI <18.5).
Radiation exposure 2 Mean DLP healthy weight (BMI of 18.5–24.9)	Mean Dose Length Product (DLP) across all screening exams performed on healthy weight patients (BMI of 18.5-24.9).
Radiation exposure 2 Mean DLP overweight (BMI of 25–29.9)	Mean Dose Length Product (DLP) across all screening exams performed on overweight patients (BMI of 25-29.9).
Radiation exposure 2 Mean DLP obese (BMI of 30 or more)	Mean Dose Length Product (DLP) across all screening exams performed on obese patients (BMI of 30 or more).
Radiation exposure 2 Mean DLP obese class I (BMI of 30-34.9)	Mean Dose Length Product (DLP) across all screening exams performed on class I obese patients (BMI of 30-34.9).
Radiation exposure 2 Mean DLP obese class II (BMI of 35-39.9)	Mean Dose Length Product (DLP) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 2 Mean DLP obese class III (BMI of 40 or greater)	Mean Dose Length Product (DLP) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 2 Mean DLP - low dose chest exams	Mean Dose Length Product (DLP) across other than routine (low dose) chest exams performed.
Radiation exposure 2 Mean DLP - routine chest exams	Mean Dose Length Product (DLP) across routine chest exams performed.




LCSR Measure Definitions

Measure	Description
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate)	Percent of screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate) during	Percent of baseline screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy). Percent of annual screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Cancer Detection Rate (CDR)	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 months.
CDR for prevalent cancers, detected at baseline exam	Number per 1000 baseline (first visit) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 mo
CDR for incident cancers, detected at annual exam	Number per 1000 annual (not baseline) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 mon
CDR for stage 0	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 0 within 12 months.
CDR for stage IA, IA1, IA1, IA3, IB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 1 within 12 months.
CDR for stage IIA, IIB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 2 within 12 months.
CDR for stage IIIA, IIIB, IIIC	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 3 within 12 months.
CDR for stage IV, IVA, IVB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 4 within 12 months.
CDR for unknown stage	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of unknown cancer stage within 12 months.
CDR for presumptive stage	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a non-histology diagnosis of cancer within 12 months.
PPV1	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months.

LCSR Measure Definitions

Measure		Description
PPV1 for lung cancers detected on percutaneous biopsies		Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on percutaneou
PPV1 for lung cancers detected on bronchoscopies		Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on bronchoscop
PPV1 for surgically detected lung cancers		Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on surgical in
PPV2a		Percent of screening exams that had a Lung-RADS assessment category of 3, 4a (typically associated with additional CT recommendation or PET/CT recommendation) that
PPV2b		Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) that had a tissue diagnosis of can
PPV3		Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) and with record of biopsy performe

LCSR Facility Characteristics : 2022-2023



Section 1 Facility Report: Preliminary data on exams performed during Jan-Dec 2023

Facility 100853 National Comparison
Jan-Dec 2023

		2023				2022	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	101752	.	1017520	.	911664
Appropriateness of screening by USPSTF criteria (%)	2013	68.57	69768 / 101752	68.51	697103 / 1017520	75.60	689184 / 911664
	2021	91.45	93056 / 101752	91.38	929808 / 1017520	92.05	839156 / 911664
Smoking cessation counselling offered (%)		61.60	62683 / 101752	61.75	628318 / 1017520	70.21	640088 / 911664
	counselling offered among current smokers (%)	66.59	38795 / 58256	66.56	389239 / 584757	75.56	399548 / 528813
Non-smoking rate		NA	0 / 0	39.90	399631 / 1001476	39.64	357151 / 900962
Adherence to annual screening		28.88	20242 / 70087	28.93	202816 / 700945	37.08	212015 / 571795
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.57	NA / 99048	3.53	NA / 990529	3.29	NA / 895092
	underweight (BMI <18.5)(mGy)	2.30	NA / 2769	2.62	NA / 27963	2.65	NA / 25083
	healthy weight (BMI of 18.5-24.9)(mGy)	2.95	NA / 23285	2.85	NA / 232992	2.61	NA / 210960
	overweight (BMI of 25-29.9)(mGy)	3.35	NA / 30952	3.36	NA / 308154	3.12	NA / 278316
	obese (BMI 30 or more)(mGy)	4.28	NA / 37451	4.20	NA / 375964	3.96	NA / 337147
	obese class I (BMI of 30-34.9)(mGy)	3.96	NA / 20919	3.91	NA / 209899	3.65	NA / 188726
	obese class II (BMI of 35-39.9)(mGy)	3.94	NA / 9657	3.90	NA / 97413	3.68	NA / 87108
	obese class III (BMI of 40 or greater)(mGy)	4.55	NA / 6875	4.34	NA / 68652	4.13	NA / 61313
	low dose CT chest exam (mGy)	3.58	NA / 97759	3.53	NA / 977841	3.28	NA / 880669
	routine chest exam (mGy)	3.61	NA / 494	4.19	NA / 5002	5.79	NA / 5776
Radiation exposure - Mean DLP	Overall	90.51	NA / 99207	90.52	NA / 991791	91.33	NA / 898730
	underweight (BMI <18.5)(mGy-cm)	64.44	NA / 2777	65.13	NA / 28000	66.49	NA / 25122
	healthy weight (BMI of 18.5-24.9)(mGy-cm)	72.45	NA / 23318	72.19	NA / 233251	73.41	NA / 211235
	overweight (BMI of 25-29.9)(mGy-cm)	85.63	NA / 30969	85.27	NA / 308443	85.80	NA / 278749
	obese (BMI of 30 or more)(mGy-cm)	107.12	NA / 37489	107.34	NA / 376243	108.50	NA / 337659
	obese class I (BMI of 30-34.9)(mGy-cm)	98.46	NA / 20940	99.16	NA / 210099	100.36	NA / 188993

Facility 100853 National Comparison
Jan-Dec 2023

		2023				2022	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	obese class II (BMI of 35-39.9)(mGy-cm)	111.98	NA / 9668	112.46	NA / 97453	112.58	NA / 87253
	obese class III (BMI of 40 or greater)(mGy-cm)	125.78	NA / 6881	124.23	NA / 68691	126.88	NA / 61413
	low dose CT chest exam (mGy-cm)	90.34	NA / 97919	90.34	NA / 979106	90.89	NA / 884280
	routine chest exam (mGy-cm)	129.31	NA / 493	132.02	NA / 5001	153.03	NA / 5802
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	11.84	12043 / 101752	11.83	120327 / 1017520	13.18	120198 / 911664
	Abnormal Interpretation Rate, at baseline exam (%)	14.06	6209 / 44150	14.37	63181 / 439753	15.66	65286 / 416838
	Abnormal Interpretation Rate, at annual exam (%)	9.93	5387 / 54234	9.70	52701 / 543520	10.84	50299 / 464191
Cancer Detection Rate (CDR) per 1000		2.30	234 / 101752	2.29	2329 / 1017520	3.51	3196 / 911664
	prevalent cancers, detected at baseline exam	2.60	115 / 44150	2.59	1140 / 439753	3.98	1659 / 416838
	incident cancers, detected at annual exam	2.01	109 / 54234	2.04	1109 / 543520	2.99	1388 / 464191
	stage 0	0.77	2 / 260	0.65	17 / 2599	0.75	28 / 3728
	stage IA, IA1, IA2, IA3, IB	38.08	99 / 260	38.36	997 / 2599	40.88	1524 / 3728
	stage IIA, IIB	7.69	20 / 260	7.20	187 / 2599	7.67	286 / 3728
	stage IIIA, IIIB, IIIC	10.00	26 / 260	12.74	331 / 2599	12.53	467 / 3728
	stage IV, IVA, IVB	7.69	20 / 260	8.96	233 / 2599	8.50	317 / 3728
	stage unknown	35.77	93 / 260	32.09	834 / 2599	29.67	1106 / 3728
	presumptive case	2.30	234 / 101752	2.29	2329 / 1017520	3.51	3196 / 911664
Positive Predictive Value 1 (PPV1)(%)		1.81	218 / 12043	1.78	2146 / 120327	2.45	2949 / 120198
	lung cancers detected on percutaneous biopsies (%)	52.08	75 / 144	52.79	748 / 1417	51.65	1081 / 2093
	lung cancers detected on bronchoscopies (%)	51.41	91 / 177	47.09	889 / 1888	45.26	1027 / 2269
	surgically detected lung cancers (%)	73.03	65 / 89	76.48	712 / 931	77.23	1201 / 1555

Facility 100853 National Comparison
Jan-Dec 2023

		2023				2022	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2a (PPV2a) (%)		0.48	47 / 9853	0.49	478 / 98057	0.86	838 / 97720
Positive Predictive Value 2b (PPV2b) (%)		7.81	171 / 2190	7.49	1668 / 22270	9.39	2111 / 22478
Positive Predictive Value 3 (PPV3) (%)		61.76	168 / 272	59.66	1618 / 2712	60.39	2032 / 3365

Facility 100853 Regional Comparison
Jan-Dec 2023

		2023							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	101752	.	382549	.	203009	.	203959
First-time screening		NA	0 / 0	55.15	210968 / 382549	56.89	115489 / 203009	57.29	116857 / 203959
Appropriateness of screening by USPSTF criteria (%)	2013	68.57	69768 / 101752	66.25	253428 / 382549	69.13	140339 / 203009	68.57	139854 / 203959
	2021	91.45	93056 / 101752	89.29	341581 / 382549	92.27	187309 / 203009	89.96	183484 / 203959
Smoking cessation counselling offered (%)		61.60	62683 / 101752	58.15	222459 / 382549	59.78	121353 / 203009	58.58	119484 / 203959
	counselling offered among current smokers (%)	66.59	38795 / 58256	62.21	131397 / 211216	62.67	72710 / 116016	63.39	74565 / 117627
Non-smoking rate		NA	0 / 0	41.21	155340 / 376934	40.95	82084 / 200448	39.82	79785 / 200340
Adherence to annual screening		28.88	20242 / 70087	27.29	75045 / 275030	24.63	37506 / 152277	25.90	38086 / 147076
	Adherence to 6 month interim assessment	24.47	1388 / 5672	23.31	4720 / 20251	16.84	2081 / 12358	21.27	2635 / 12387
	Adherence to 3 month interim assessment	28.93	980 / 3387	28.99	3305 / 11399	20.83	1355 / 6506	27.13	1939 / 7147
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.57	NA / 99048	4.17	NA / 366504	3.68	NA / 199470	2.98	NA / 198560
	underweight (BMI <18.5)(mGy)	2.30	NA / 2769	3.16	NA / 9292	2.53	NA / 4583	2.25	NA / 5201
	healthy weight (BMI of 18.5-24.9)(mGy)	2.95	NA / 23285	3.42	NA / 88560	3.03	NA / 50156	2.41	NA / 47996
	overweight (BMI of 25-29.9)(mGy)	3.35	NA / 30952	3.99	NA / 115344	3.56	NA / 64729	2.87	NA / 61341
	obese (BMI 30 or more)(mGy)	4.28	NA / 37451	4.98	NA / 134032	4.48	NA / 70741	3.62	NA / 72161
	obese class I (BMI of 30-34.9)(mGy)	3.96	NA / 20919	4.67	NA / 76408	4.17	NA / 41307	3.36	NA / 40001

Facility 100853 Regional Comparison
Jan-Dec 2023

		2023							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	obese class II (BMI of 35-39.9)(mGy)	3.94	NA / 9657	4.77	NA / 34999	4.15	NA / 18237	3.34	NA / 18339
	obese class III (BMI of 40 or greater)(mGy)	4.55	NA / 6875	5.14	NA / 22625	4.90	NA / 11197	3.62	NA / 13821
	low dose CT chest exam (mGy)	3.58	NA / 97759	4.17	NA / 363314	3.71	NA / 194036	2.98	NA / 197235
	routine chest exam (mGy)	3.61	NA / 494	4.27	NA / 2286	5.17	NA / 798	6.16	NA / 553
Radiation exposure - Mean DLP	Overall	90.51	NA / 99207	90.96	NA / 365402	85.45	NA / 198792	90.39	NA / 199618
	underweight (BMI <18.5)(mGy-cm)	64.44	NA / 2777	63.91	NA / 9288	64.99	NA / 4592	66.86	NA / 5233
	healthy weight (BMI of 18.5-24.9)(mGy-cm)	72.45	NA / 23318	71.62	NA / 88526	70.37	NA / 50239	73.77	NA / 48285
	overweight (BMI of 25-29.9)(mGy-cm)	85.63	NA / 30969	84.54	NA / 115304	81.47	NA / 64847	86.46	NA / 61703
	obese (BMI of 30 or more)(mGy-cm)	107.12	NA / 37489	108.17	NA / 133942	102.27	NA / 70852	108.11	NA / 72516
	obese class I (BMI of 30-34.9)(mGy-cm)	98.46	NA / 20940	99.04	NA / 76373	94.73	NA / 41383	100.68	NA / 40226
	obese class II (BMI of 35-39.9)(mGy-cm)	111.98	NA / 9668	113.87	NA / 34966	106.60	NA / 18268	113.14	NA / 18424
	obese class III (BMI of 40 or greater)(mGy-cm)	125.78	NA / 6881	129.30	NA / 22603	122.05	NA / 11201	122.16	NA / 13866
	low dose CT chest exam (mGy-cm)	90.34	NA / 97919	90.61	NA / 362212	85.24	NA / 193362	90.08	NA / 198291
	routine chest exam (mGy-cm)	129.31	NA / 493	140.42	NA / 2286	163.39	NA / 796	211.04	NA / 556
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	11.84	12043 / 101752	11.06	42329 / 382549	11.75	23863 / 203009	12.24	24968 / 203959

Facility 100853 Regional Comparison
Jan-Dec 2023

		2023							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	Abnormal Interpretation Rate, at baseline exam (%)	14.06	6209 / 44150	13.27	20460 / 154195	14.52	13029 / 89762	14.60	13767 / 94293
	Abnormal Interpretation Rate, at annual exam (%)	9.93	5387 / 54234	9.40	19419 / 206684	9.53	10325 / 108368	10.04	10808 / 107598
Cancer Detection Rate (CDR) per 1000		2.30	234 / 101752	2.53	967 / 382549	1.36	276 / 203009	2.00	408 / 203959
	prevalent cancers, detected at baseline exam	2.60	115 / 44150	3.11	479 / 154195	1.58	142 / 89762	2.36	223 / 94293
	incident cancers, detected at annual exam	2.01	109 / 54234	2.19	452 / 206684	1.20	130 / 108368	1.69	182 / 107598
	stage 0	0.77	2 / 260	0.28	3 / 1089	1.01	3 / 296	0.00	0 / 485
	stage IA, IA1, IA2, IA3, IB	38.08	99 / 260	41.87	456 / 1089	34.80	103 / 296	37.73	183 / 485
	stage IIA, IIB	7.69	20 / 260	7.99	87 / 1089	6.76	20 / 296	9.28	45 / 485
	stage IIIA, IIIB, IIIC	10.00	26 / 260	11.57	126 / 1089	10.14	30 / 296	11.34	55 / 485
	stage IV, IVA, IVB	7.69	20 / 260	9.18	100 / 1089	10.47	31 / 296	12.16	59 / 485
	stage unknown	35.77	93 / 260	29.11	317 / 1089	36.82	109 / 296	29.48	143 / 485
	presumptive case	2.30	234 / 101752	2.53	967 / 382549	1.36	276 / 203009	2.00	408 / 203959
Positive Predictive Value 1 (PPV1)(%)		1.81	218 / 12043	2.11	893 / 42329	1.08	257 / 23863	1.57	392 / 24968
	lung cancers detected on percutaneous biopsies (%)	52.08	75 / 144	50.10	249 / 497	54.97	94 / 171	59.15	126 / 213
	lung cancers detected on bronchoscopies (%)	51.41	91 / 177	45.16	415 / 919	47.69	93 / 195	59.27	163 / 275
	surgically detected lung cancers (%)	73.03	65 / 89	76.90	323 / 420	70.69	82 / 116	75.90	126 / 166

Facility 100853 Regional Comparison
Jan-Dec 2023

		2023							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2a (PPV2a) (%)		0.48	47 / 9853	0.61	210 / 34280	0.32	64 / 19707	0.34	70 / 20306
Positive Predictive Value 2b (PPV2b) (%)		7.81	171 / 2190	8.49	683 / 8049	4.64	193 / 4156	6.91	322 / 4662
Positive Predictive Value 3 (PPV3) (%)		61.76	168 / 272	59.71	667 / 1117	58.70	189 / 322	67.67	314 / 464

Section 2 Facility Report: Exams performed during Jan-Dec 2022 with follow-up through Dec 2023

***Facility 100853 National Comparison
Jan-Dec 2022 with follow-up through Dec 2023***

		2022			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
All Exams		.	91167	.	911664
First-time screening		NA	0 / 0	58.30	531544 / 911664
Appropriateness of screening by USPSTF criteria (%)	2013	75.69	69003 / 91167	75.60	689184 / 911664
	2021	91.94	83823 / 91167	92.05	839156 / 911664
Smoking cessation counselling offered (%)		70.17	63972 / 91167	70.21	640088 / 911664
	counselling offered among current smokers (%)	75.54	39892 / 52811	75.56	399548 / 528813
Non-smoking rate		NA	0 / 0	39.64	357151 / 900962
Adherence to annual screening		37.11	21194 / 57108	37.08	212015 / 571795
	Adherence to 6 month interim assessment	24.80	1526 / 6154	24.72	15156 / 61300
	Adherence to 3 month interim assessment	32.04	1113 / 3474	32.55	11152 / 34258
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.29	NA / 89464	3.29	NA / 895092
	underweight (BMI <18.5)(mGy)	2.60	NA / 2543	2.65	NA / 25083
	healthy weight (BMI of 18.5-24.9)(mGy)	2.51	NA / 21144	2.61	NA / 210960
	overweight (BMI of 25-29.9)(mGy)	3.14	NA / 27710	3.12	NA / 278316
	obese (BMI 30 or more)(mGy)	4.00	NA / 33660	3.96	NA / 337147
	obese class I (BMI of 30-34.9)(mGy)	3.82	NA / 18665	3.65	NA / 188726
	obese class II (BMI of 35-39.9)(mGy)	3.49	NA / 8788	3.68	NA / 87108
	obese class III (BMI of 40 or greater)(mGy)	4.09	NA / 6207	4.13	NA / 61313
	low dose CT chest exam (mGy)	3.29	NA / 88019	3.28	NA / 880669
	routine chest exam (mGy)	4.83	NA / 598	5.79	NA / 5776
Radiation exposure - Mean DLP	Overall	91.23	NA / 89829	91.33	NA / 898730
	underweight (BMI <18.5)(mGy-cm)	66.68	NA / 2543	66.49	NA / 25122
	healthy weight (BMI of 18.5-24.9)(mGy-cm)	72.57	NA / 21156	73.41	NA / 211235

***Facility 100853 National Comparison
Jan-Dec 2022 with follow-up through Dec 2023***

		2022			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
	overweight (BMI of 25-29.9)(mGy-cm)	86.27	NA / 27764	85.80	NA / 278749
	obese (BMI of 30 or more)(mGy-cm)	108.52	NA / 33718	108.50	NA / 337659
	obese class I (BMI of 30-34.9)(mGy-cm)	100.22	NA / 18696	100.36	NA / 188993
	obese class II (BMI of 35-39.9)(mGy-cm)	112.61	NA / 8805	112.58	NA / 87253
	obese class III (BMI of 40 or greater)(mGy-cm)	126.81	NA / 6217	126.88	NA / 61413
	low dose CT chest exam (mGy-cm)	90.72	NA / 88378	90.89	NA / 884280
	routine chest exam (mGy-cm)	160.44	NA / 603	153.03	NA / 5802
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.18	12019 / 91167	13.18	120198 / 911664
	Abnormal Interpretation Rate, at baseline exam (%)	15.45	6440 / 41696	15.66	65286 / 416838
	Abnormal Interpretation Rate, at annual exam (%)	11.01	5104 / 46355	10.84	50299 / 464191
Cancer Detection Rate (CDR) per 1000		3.64	332 / 91167	3.51	3196 / 911664
	prevalent cancers, detected at baseline exam	4.05	169 / 41696	3.98	1659 / 416838
	incident cancers, detected at annual exam	3.17	147 / 46355	2.99	1388 / 464191
	stage 0	0.78	3 / 385	0.75	28 / 3728
	stage IA, IA1, IA2, IA3, IB	38.96	150 / 385	40.88	1524 / 3728
	stage IIA, IIB	5.71	22 / 385	7.67	286 / 3728
	stage IIIA, IIIB, IIIC	14.29	55 / 385	12.53	467 / 3728
	stage IV, IVA, IVB	9.35	36 / 385	8.50	317 / 3728
	stage unknown	30.91	119 / 385	29.67	1106 / 3728
	presumptive case	3.64	332 / 91167	3.51	3196 / 911664
Positive Predictive Value 1 (PPV1)(%)		2.57	309 / 12019	2.45	2949 / 120198
	lung cancers detected on percutaneous biopsies (%)	49.51	101 / 204	51.65	1081 / 2093
	lung cancers detected on bronchoscopies (%)	53.04	122 / 230	45.26	1027 / 2269

Facility 100853 National Comparison
Jan-Dec 2022 with follow-up through Dec 2023

		2022			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
surgically detected lung cancers (%)		81.63	120 / 147	77.23	1201 / 1555
Positive Predictive Value 2a (PPV2a) (%)		0.78	76 / 9788	0.86	838 / 97720
Positive Predictive Value 2b (PPV2b) (%)		10.44	233 / 2231	9.39	2111 / 22478
Positive Predictive Value 3 (PPV3) (%)		64.71	220 / 340	60.39	2032 / 3365

Facility 100853: Regional Comparison
Jan-Dec 2022 with follow-up through Dec 2023

		2022							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	91167	.	359744	.	180416	.	190106
First-time screening		NA	0 / 0	57.94	208437 / 359744	61.57	111080 / 180416	60.83	115645 / 190106
Appropriateness of screening by USPSTF criteria (%)	2013	75.69	69003 / 91167	74.07	266462 / 359744	75.00	135316 / 180416	76.18	144825 / 190106
	2021	91.94	83823 / 91167	90.82	326720 / 359744	92.66	167181 / 180416	91.80	174511 / 190106
Smoking cessation counselling offered (%)		70.17	63972 / 91167	67.40	242459 / 359744	67.53	121828 / 180416	70.84	134665 / 190106
	counselling offered among current smokers (%)	75.54	39892 / 52811	72.20	145629 / 201699	71.22	74800 / 105026	76.49	85915 / 112326
Non-smoking rate		NA	0 / 0	41.21	146836 / 356315	40.44	72297 / 178780	39.32	73972 / 188114
Adherence to annual screening		37.11	21194 / 57108	36.29	84269 / 232234	31.28	39037 / 124802	33.83	40318 / 119189
	Adherence to 6 month interim assessment	24.80	1526 / 6154	23.50	5449 / 23192	17.47	2584 / 14788	22.13	2924 / 13214
	Adherence to 3 month interim assessment	32.04	1113 / 3474	30.45	3814 / 12526	20.89	1549 / 7415	29.80	2146 / 7201
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.29	NA / 89464	3.48	NA / 352356	2.92	NA / 176254	3.36	NA / 188530
	underweight (BMI <18.5)(mGy)	2.60	NA / 2543	3.12	NA / 9129	3.05	NA / 4190	3.59	NA / 5185
	healthy weight (BMI of 18.5-24.9)(mGy)	2.51	NA / 21144	2.72	NA / 85734	2.33	NA / 44791	2.71	NA / 44487
	overweight (BMI of 25-29.9)(mGy)	3.14	NA / 27710	3.30	NA / 111729	2.72	NA / 57504	3.21	NA / 56965
	obese (BMI 30 or more)(mGy)	4.00	NA / 33660	4.20	NA / 129289	3.56	NA / 62724	4.07	NA / 67334
	obese class I (BMI of 30-34.9)(mGy)	3.82	NA / 18665	3.87	NA / 73294	3.22	NA / 36573	3.77	NA / 37218

Facility 100853: Regional Comparison
Jan-Dec 2022 with follow-up through Dec 2023

		2022							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	obese class II (BMI of 35-39.9)(mGy)	3.49	NA / 8788	3.96	NA / 33348	3.36	NA / 15732	3.81	NA / 16627
	obese class III (BMI of 40 or greater)(mGy)	4.09	NA / 6207	4.44	NA / 22647	3.79	NA / 10419	4.12	NA / 13489
	low dose CT chest exam (mGy)	3.29	NA / 88019	3.46	NA / 348355	2.92	NA / 171305	3.31	NA / 186716
	routine chest exam (mGy)	4.83	NA / 598	6.39	NA / 2415	5.61	NA / 1314	12.56	NA / 1070
Radiation exposure - Mean DLP	Overall	91.23	NA / 89829	91.19	NA / 351787	87.25	NA / 178245	92.36	NA / 188737
	underweight (BMI <18.5)(mGy-cm)	66.68	NA / 2543	65.17	NA / 9115	64.82	NA / 4212	68.10	NA / 5189
	healthy weight (BMI of 18.5-24.9)(mGy-cm)	72.57	NA / 21156	72.91	NA / 85539	71.86	NA / 45046	76.61	NA / 44522
	overweight (BMI of 25-29.9)(mGy-cm)	86.27	NA / 27764	85.19	NA / 111567	82.98	NA / 57888	88.18	NA / 57008
	obese (BMI of 30 or more)(mGy-cm)	108.52	NA / 33718	108.45	NA / 129089	104.29	NA / 63191	109.59	NA / 67381
	obese class I (BMI of 30-34.9)(mGy-cm)	100.22	NA / 18696	99.85	NA / 73132	97.09	NA / 36850	102.60	NA / 37242
	obese class II (BMI of 35-39.9)(mGy-cm)	112.61	NA / 8805	112.33	NA / 33326	107.87	NA / 15844	113.96	NA / 16647
	obese class III (BMI of 40 or greater)(mGy-cm)	126.81	NA / 6217	129.64	NA / 22631	123.24	NA / 10497	122.73	NA / 13492
	low dose CT chest exam (mGy-cm)	90.72	NA / 88378	90.44	NA / 347786	86.73	NA / 173296	91.27	NA / 186914
	routine chest exam (mGy-cm)	160.44	NA / 603	171.75	NA / 2415	167.75	NA / 1315	290.69	NA / 1079
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.18	12019 / 91167	12.54	45101 / 359744	13.47	24307 / 180416	13.69	26019 / 190106
	Abnormal Interpretation Rate, at baseline exam (%)	15.45	6440 / 41696	14.79	22939 / 155068	16.25	13482 / 82969	16.07	15071 / 93771

Facility 100853: Regional Comparison
Jan-Dec 2022 with follow-up through Dec 2023

		2022							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Abnormal Interpretation Rate, at annual exam (%)		11.01	5104 / 46355	10.48	19368 / 184885	11.06	10400 / 93993	11.25	10657 / 94764
Cancer Detection Rate (CDR) per 1000		3.64	332 / 91167	3.82	1376 / 359744	2.03	366 / 180416	3.07	583 / 190106
	prevalent cancers, detected at baseline exam	4.05	169 / 41696	4.37	678 / 155068	2.64	219 / 82969	3.42	321 / 93771
	incident cancers, detected at annual exam	3.17	147 / 46355	3.30	611 / 184885	1.51	142 / 93993	2.73	259 / 94764
	stage 0	0.78	3 / 385	0.61	10 / 1648	1.00	4 / 400	1.09	8 / 735
	stage IA, IA1, IA2, IA3, IB	38.96	150 / 385	44.72	737 / 1648	35.50	142 / 400	35.78	263 / 735
	stage IIA, IIB	5.71	22 / 385	7.71	127 / 1648	7.75	31 / 400	7.76	57 / 735
	stage IIIA, IIIB, IIIC	14.29	55 / 385	11.23	185 / 1648	12.25	49 / 400	15.51	114 / 735
	stage IV, IVA, IVB	9.35	36 / 385	8.86	146 / 1648	7.75	31 / 400	9.12	67 / 735
	stage unknown	30.91	119 / 385	26.88	443 / 1648	35.75	143 / 400	30.75	226 / 735
	presumptive case	3.64	332 / 91167	3.82	1376 / 359744	2.03	366 / 180416	3.07	583 / 190106
Positive Predictive Value 1 (PPV1)(%)		2.57	309 / 12019	2.82	1273 / 45101	1.40	340 / 24307	2.16	562 / 26019
	lung cancers detected on percutaneous biopsies (%)	49.51	101 / 204	50.30	415 / 825	50.42	119 / 236	60.66	185 / 305
	lung cancers detected on bronchoscopies (%)	53.04	122 / 230	44.87	485 / 1081	48.57	119 / 245	51.68	185 / 358
	surgically detected lung cancers (%)	81.63	120 / 147	76.19	560 / 735	79.64	133 / 167	79.61	242 / 304
Positive Predictive Value 2a (PPV2a) (%)		0.78	76 / 9788	1.08	392 / 36408	0.42	85 / 20107	0.62	132 / 21127

Facility 100853: Regional Comparison
Jan-Dec 2022 with follow-up through Dec 2023

		2022							
Measure		Your Facility (100853)		Metropolitan		Freestanding		South Atlantic Division	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2b (PPV2b) (%)		10.44	233 / 2231	10.13	881 / 8693	6.07	255 / 4200	8.79	430 / 4892
Positive Predictive Value 3 (PPV3) (%)		64.71	220 / 340	60.20	835 / 1387	64.36	251 / 390	69.24	421 / 608

Maintenance of Certification (MOC): Practice Quality Improvement (PQI)

With the implementation of Continuous Certification and its annual look-back approach, diplomates must have completed at least one PQI Project or Participatory Quality Improvement Activity in the previous three years at each annual look-back. A PQI Project or Activity may be conducted repeatedly or continuously to meet PQI

requirements. (<https://www.theabr.org/diagnostic-radiology/maintenance-of-certification/improvement-medical-practice/participatory-activities>)

The National Radiology Data Registry has been approved by the American Board of Radiology for fulfilling MOC Part IV requirements. The names of the physicians are listed below.

NPI	Last Name	First Name
994	Doctor	Green
995	Doctor	Black
996	Doctor	White
997	Doctor	Brown
998	Doctor	Gray

Promote your participation in NRDR™! Download your marketing toolkit today.

acr.org/LCSRtoolkit

CONTACT US

1.800.227.5463, ext. 3535

nrdn@acr.org | nrdn.acr.org

